Genmab
GMAB

$26.48

1.07%

Market Cap: $16.8B

About: Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Employees: 2,526

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 14 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0.18% less ownership

Funds ownership: 73.85% [Q1] → 73.66% (-0.18%) [Q2]

3% less funds holding

Funds holding: 225 [Q1] → 218 (-7) [Q2]

16% less capital invested

Capital invested by funds: $1.46B [Q1] → $1.23B (-$235M) [Q2]

21% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 33

27% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 93

74% less call options, than puts

Call options by funds: $178K | Put options by funds: $696K

See Fund Rankings

Research analyst outlook

14 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$31

17%

upside

Avg. target

$47

78%

upside

High target

$50

89%

upside

14 analyst ratings

12 positive

86%

2 neutral

14%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 124 / 283 met price target	89%upside $50	Buy Reiterated	16 Sept 2024
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 124 / 283 met price target	89%upside $50	Buy Reiterated	13 Sept 2024
Morgan Stanley Vikram Purohit 80% 1-year accuracy 4 / 5 met price target	17%upside $31	Equal-Weight Maintained	11 Sept 2024
Truist Securities Asthika Goonewardene 45% 1-year accuracy 10 / 22 met price target	89%upside $50	Buy Maintained	9 Sept 2024
Morgan Stanley Vikram Purohit 80% 1-year accuracy 4 / 5 met price target	17%upside $31	Equal-Weight Reinstated	4 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about GMAB published over the past 30 days

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part stu.

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohort Responses with Rina-S were observed across FRα expression levels Phase 3 trial will further evaluate the safety and efficacy of Rina-S at 120 mg/m 2 in patients with advanced ovarian cancer Genmab A/S (Nasdaq: GMAB) announced today new data from the Phase 1/2 study of rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate (ADC), demonstrated a confirmed objective response rate (ORR) of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every 3 weeks (Q3W), regardless of FRα expression levels. These data were from the dose expansion part of a multi-part study evaluating the safety and efficacy of single-agent Rina-S in ovarian cancer (OC) and endometrial cancer (EC).

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 10, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 11,729 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 26, 2024 Genmab A/S (Nasdaq: GMAB ) a nnounced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 2 2 nd Annual Global Healthcare Conference at 1 : 05 P M E D T / 7 : 05 P M CEST on September 4 , 202 4.

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Un.

$TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma$

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Company Announcement TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy COPENHAGEN, Denmark; August 19, 2024 – Genmab A/S (Nasdaq: GMAB) today announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY® (epcoritamab) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for the treatment of this patient population in the European Union (EU), as well as the European Economic Area (EEA) countries (Iceland, Liechtenstein, Norway) and Northern Ireland.

$TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma$

Genmab Announces Changes to its Executive Committee

Media Release COPENHAGEN, Denmark; August 16, 2024 Rayne Waller joins as Executive Vice President and Chief Technology Officer Brad Bailey appointed as Executive Vice President and Chief Commercial Officer Anthony Mancini, Executive Vice President and Chief Operating Officer, will leave Genmab to pursue other opportunities Genmab A/S (Nasdaq: GMAB ) today announced changes to its Executive Committee to support Genmab's growth and evolution into a fully integrated biotech innovation powerhouse. Genmab's Executive Committee will include Rayne Waller in the newly created role of Executive Vice President and Chief Technology Officer and Brad Bailey in the newly created role of Executive Vice President and Chief Commercial Officer.

Genmab Announces Changes to its Executive Committee

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 13, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Capital Increase in Genmab as a Result of Employee Warrant Exercise

See News Rankings